The Case for WHO PQ in Nigeria

The attainment of WHO PQ by the pharmaceutical manufacturers in Nigeria will establish their capability to produce medicines that consistently meet stringent standards of quality in line with WHO specifications and global standards.

This will provide opportunities for increased sales and market access by conferring eligibility for international, donor-sponsored tenders for medicines; improved capacity to manufacture products for entry into stringently regulated markets; increased potential to compete successfully for contract manufacture for local markets; and faster registration. Thus, facilitating international procurement and distribution of locally produced medicines in Nigeria.
Annually billions of dollars worth of products are donated to Africa without local participation in the tender because they are not WHO prequalified.


This questionnaire is intended to facilitate the process of evaluating pharmaceutical manufacturers interested in participating in the above-mentioned program. The intention is to identify manufacturers capable of manufacturing antimalarial medicines that are compliant with World Health Organization (WHO) Good Manufacturing Practices (GMP), and successful prequalification of the medicinal product.

Click Here To Fill Questionnaire
Excepts from our stakeholders

Stake Holders

Challenges confronting WHO PQ in Nigeria

One of the major barriers to achieving WHO PQ in Nigeria is the high upfront cost. Pharmaceutical manufacturers would need to invest several millions of dollars to upgrade their factories and to hire or train qualified professional and technical personnel in order to meet WHO PQ requirements. Unfortunately, without the support from government or donor agencies, most Nigerian pharmaceutical companies lack the capacity for such enormous capital investment. Another significant barrier is the poor technical support and limited expertise about achieving WHO PQ. Most Nigerian pharmaceutical companies have limited information on the specific requirements for WHO PQ and the application process. Attaining WHO PQ is a highly technical process, requiring comprehensive technical and professional support from experts in the field.

Proposed solution - Transformational change for the pharmaceutical industry in Nigeria

This project is by far Nigeria’s biggest pharmaceutical intervention and will achieve the first ever WHO PQ of pharmaceutical companies in Nigeria. It will have a tremendous impact on the Nigerian health system and build a national capacity for sustainable manufacturing, as well as position the pharmaceutical industry in Nigeria as a global competitor. Work plan starting from - Selection

WHO PQ Workplan

The Overview


Benefit & Impact

WHO PQ will create huge public health and economic impact in Nigeria by ensuring an increased availability of quality, efficacious and safe medicines and reduce over reliance on imports for public health interventions. Therefore, this ongoing initiative by NIPRD and Bloom Public Health is a golden opportunity that Nigerian pharmaceutical companies must leverage to increase their capacity for local manufacturing and strengthen Nigeria’s pharmaceutical sector.

Reach Out To Us

Together, We Can Achieve Better Healthcare in Africa.